PDE7A1/3 Antibody (F-8): sc-166550
- PDE7A1/3 Antibody (F-8) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against amino acids 1-50 of PDE7A1 of human origin
- recommended for detection of PDE7A1 and PDE7A3 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgGκ BP-HRP is the preferred secondary detection reagent for PDE7A1/3 Antibody (F-8) for WB applications. This reagent is now offered in a bundle with PDE7A1/3 Antibody (F-8) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
PDE7A1/3 Antibody (F-8) is a mouse monoclonal IgG2b antibody that detects phosphodiesterase 7A1 (PDE7A1) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PDE7A1 plays a crucial role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP), a vital second messenger involved in various physiological processes, including cardiac function and neuronal signaling. By hydrolyzing cAMP to 5′AMP, PDE7A1 helps modulate signaling pathways that influence smooth muscle relaxation and lipolysis, making PDE7A1 essential for maintaining cardiovascular health and metabolic homeostasis. PDE7A1 is predominantly expressed in skeletal muscle, where PDE7A1 contributes to the fine-tuning of muscle contraction and energy utilization. Understanding PDE7A1 function is important for developing therapeutic strategies targeting cardiovascular diseases and metabolic disorders, as dysregulation of cAMP signaling is often implicated in these conditions. Anti-PDE7A1 antibody (F-8) is an invaluable tool for researchers investigating the intricate roles of phosphodiesterases in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PDE7A1/3 Antibody (F-8) References:
- Identification of purine inhibitors of phosphodiesterase 7 (PDE7). | Pitts, WJ., et al. 2004. Bioorg Med Chem Lett. 14: 2955-8. PMID: 15125967
- Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. | Bernardelli, P., et al. 2004. Bioorg Med Chem Lett. 14: 4627-31. PMID: 15324877
- Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. | Guo, J., et al. 2009. Bioorg Med Chem Lett. 19: 1935-8. PMID: 19272774
- Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold. | Sánchez, AI., et al. 2014. Org Biomol Chem. 12: 4233-42. PMID: 24838636
- Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging. | Thomae, D., et al. 2015. Nucl Med Biol. 42: 975-81. PMID: 26330158
- Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7. | Sharma, H., et al. 2019. Curr Comput Aided Drug Des. 15: 225-234. PMID: 30280674
- Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions. | Szczypka, M. 2020. Int J Mol Sci. 21: PMID: 32854348
- PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis. | Świerczek, A., et al. 2021. Pharmaceutics. 13: PMID: 33919375
- The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis. | Benítez-Fernández, R., et al. 2022. Int J Mol Sci. 23: PMID: 36430856
- CD3- and CD28-dependent induction of PDE7 required for T cell activation. | Li, L., et al. 1999. Science. 283: 848-51. PMID: 9933169
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PDE7A1/3 Antibody (F-8) | sc-166550 | 200 µg/ml | $316.00 | |||
PDE7A1/3 Antibody (F-8): m-IgGκ BP-HRP Bundle | sc-521652 | 200 µg Ab, 40 µg BP | $354.00 |